

## ASX Appendix 4D

### Half-Year Financial Report to 31 December 2015

#### 1. Details of reporting period

Name of Entity	Cynata Therapeutics Limited ("the Company")
ABN	98 104 037 372
Reporting Period	31 December 2015
Previous Corresponding Period	31 December 2014

#### 2. Results for announcement to the market

				\$
Revenues from ordinary activities	Up	78.97%	to	77,592
Loss for the half-year	Up	73.97%	to	2,468,220
Total comprehensive loss for the half-year attributable to members	Up	73.87%	to	2,468,220
		Amount Per Security		Franked Amount Per Security
Final Dividend		Nil		Nil
Interim Dividend		Nil		Nil
Previous Corresponding Period		Nil		Nil
Record Date for Determining Entitlements	Not Applicable			

Brief explanation of any of the figures reported above necessary to enable figures to be understood:

For further information, refer to the review of operations contained in the directors' report, which forms part of the attached consolidated financial statements.

#### 3. Net tangible asset backing

	31 December 2015	31 December 2014
Net tangible backing per ordinary security	9.19 cents	9.76 cents

#### 4. Details of entities over which control has been gained or lost during the period

N/A

#### 5. Details of Dividends

No dividend has been paid or recommended to be paid for the half-year ended 31 December 2015.

**6. Details of dividend reinvestment plans**

N/A

**7 Details of associate and joint venture entities**

N/A

**8. Foreign entities**

N/A

**9. Audit**

This report has been based on accounts that have been subject to an audit review. There are no items of dispute with the auditor and the audit review is not subject to qualification.



Dr Ross Macdonald  
**Managing Director**

26 February 2016